Hsp70 fusion protein conjugates and uses thereof
AssigneeAlternative Innovative Technologies LLC
InventorsSergei B. Onikienko, Alex Nivorozhkin, Alexander V. Zemlyanoi, Mikhail Viktorovich Shorokhov, Vladimir Ivanovich Pereguda, Valery Aleksandrovich Chereshnev
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel therapies that utilize HSP70 fusion proteins for the treatment of disorders or conditions regulated by HSP70.
Claims30
An HSP70 fusion protein comprising (i) a first HSP70 domain fused to (ii) a second Fc domain, wherein the first and second domains are optionally linked by a third linker domain.
A pharmaceutical composition comprising an HSP70 fusion protein, wherein the HSP70 fusion protein comprises (i) a first HSP70 domain fused to (ii) a second Fc domain, wherein the first and second domains are optionally linked by a third linker domain, and pharmaceutically acceptable carrier.
A method of treatment of an HSP70 related disorder or condition, wherein the method comprises administering to a subject a therapeutically effective amount of HSP70 fusion protein, and wherein the HSP70 fusion protein comprises (i) a first HSP70 domain fused to (ii) a second Fc domain, wherein the first and second domains are optionally linked by a third linker domain,
- such that the HSP70 related disorder or condition is treated in the subject.
A method to increase performance, alleviate fatigue syndrome, or treat muscle damage or muscle degeneration comprising administering to a mammal a therapeutically effective amount of HSP70 fusion protein, and wherein the HSP70 fusion protein comprises (i) a first HSP70 domain fused to (ii) a second Fc domain, wherein the first and second domains are optionally linked by a third linker domain,
- such that performance is increased, the fatigue syndrome is alleviated, or the muscle damage or muscle degeneration is treated in the mammal.
A method of radioimmunotherapy comprising administering to a subject a therapeutically effective amount of HSP70 fusion protein, wherein the HSP70 fusion protein comprises (i) a first HSP70 domain fused to (ii) a second Fc domain, wherein the first and second domains are optionally linked by a third linker domain, and wherein the HSP70 fusion protein is labeled with one or more radioactive isotopes,
- such that cancer is treated in the subject.
Dependencies are inferred from the claim text.